NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies

被引:139
|
作者
McDonagh, TA
Holmer, S
Raymond, I
Luchner, A
Hildebrant, P
Dargie, HJ
机构
[1] Univ Glasgow, Royal Infirm, Dept Cardiol, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G31 2ER, Lanark, Scotland
[3] Univ Copenhagen, Friedrichsberg Hosp, Copenhagen, Denmark
关键词
epidemiological studies; heart failure; cardio-renal distress;
D O I
10.1016/j.ejheart.2004.01.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many studies have shown that the B-type natriuretic peptides (BNP and NT-proBNP) are proven diagnostic markers for heart failure due to left ventricular systolic dysfunction. The manner in which they are to be used is still being unravelled; most single centre studies have chosen the best concentration of the peptide on ROC analysis as their cut-point resulting in numerous different values for both BNP and NT-proBNP appearing in the literature. We report a different approach of defining an age and sex corrected abnormal concentration for NT-proBNP, derived from normal individuals within a large sample of 3051 subjects pooled from three European epidemiology studies and applying that to the entire population to detect HF and LVD. Three thousand and fifty one subjects were studied. Of these 10% (305) had significant LVD and 3.1% (94) had HE The median concentrations of NT-proBNP (IQR) in normals, those with LVD and in heart failure subjects were 20 pg/ml (10.30), 117.3 pg/ml (28.145) and 269.6 pg/ml (54.323), P<0.001, respectively. The area under the ROC curve for NT-proBNP for the detection of 'heart failure' was 0.85 and 0.69 for LVD. NT-proBNP was an independent predictor of the presence of HF on multivariate analysis. An abnormal NT-proBNP was defined as being > 95th centile for normals, age and sex corrected, and diagnosed HF with a sensitivity of 75% and a negative predictive value of 99%. In an additional analysis in a breathless subgroup of our population, in 30% a raised NT-proBNP concentration could be explained by HF due to LVD, in another 64% the high BNP level was associated with some other structural of functional cardiac abnormality or renal impairment. We were unable to assign a possible cause to the high NT-proBNP values in 5.9% of this breathless subgroup of the population. An abnormal NT-proBNP concentration is an accurate diagnostic test both for the exclusion of HF in the population and in ruling out LVD in breathless subjects. An elevated NT-proBNP merely indicates the presence of 'cardio-renal distress' and should prompt referral for further investigation. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:269 / 273
页数:5
相关论文
共 50 条
  • [21] Stability of NT-ProBNP in patients with systolic heart failure
    Jimenez-Navarro, Manuel F.
    Fernandez-Moyano, Maria A.
    Dominguez-Franco, Antonio
    Gomez-Doblas, Juan J.
    Molero, Encarnacion
    Gomez-Hernandez, Gemma
    Morell, Miguel
    de Teresa-Galvan, Eduardo
    REVISTA ESPANOLA DE CARDIOLOGIA, 2006, 59 (10): : 1075 - 1078
  • [22] The Potential Role of Salivary NT-proBNP in Heart Failure
    Rammos, Aidonis
    Bechlioulis, Aris
    Kalogeras, Petros
    Watson, Chris J.
    Salvo, Pietro
    Lomonaco, Tommaso
    Kardakari, Olga
    Tripoliti, Evanthia E.
    Goletsis, Yorgos
    Fotiadis, Dimitris I.
    Katsouras, Christos S.
    Michalis, Lampros K.
    Naka, Katerina K.
    LIFE-BASEL, 2023, 13 (09):
  • [23] Interview: NT-proBNP: Therapy Monitoring in Heart Failure
    Leitner, H.
    Moertl, Deddo
    JOURNAL FUR KARDIOLOGIE, 2018, 25 (7-8): : 210 - 210
  • [24] Prognosis of decompensated heart failure: role of NT-proBNP
    Ferreira, S.
    Almeida, R.
    Guerrero, H.
    Ferreira, S. U.
    Fonseca, L.
    Azevedo, A.
    Ferreira, A.
    Bettencourt, P.
    EUROPEAN HEART JOURNAL, 2005, 26 : 71 - 71
  • [25] NT-proBNP The Gold Standard Biomarker in Heart Failure
    Mckie, Paul M.
    Burnett, John C., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (22) : 2437 - 2439
  • [26] NT-proBNP in Heart Failure With Preserved Ejection Fraction
    Tanaka, Atsushi
    Node, Koichi
    JACC-HEART FAILURE, 2020, 8 (07) : 596 - 597
  • [27] Combining NT-PROBNP and GFR to predict prognosis in patients with heart failure:: An analysis from the international collaborative of NT-proBNP (ICON) study
    van Kimmenade, RR
    Januzzi, JL
    Lainchbury, JG
    Bayes-Genis, A
    Santalo, M
    Ordoñez, J
    Richards, MA
    Pinto, YM
    CIRCULATION, 2005, 112 (17) : U819 - U819
  • [28] NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy
    Hartmann, F
    Packer, M
    Coats, AJS
    Fowler, MB
    Krum, H
    Mohacsi, P
    Rouleau, JL
    Tendera, M
    Castaigne, A
    Trawinski, J
    Amann-Zalan, I
    Hoersch, S
    Katus, HA
    EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) : 343 - 350
  • [29] A novel NT-proBNP assay for heart failure diagnosis: A prospective, multicenter clinical trial
    Guidi, Jessica L.
    Allen, Brandon R.
    Headden, Gary
    Winden, Nicole
    Alahapperuma, Dileepa
    Christenson, Robert H.
    Peacock, W. Franklin
    Januzzi, James L.
    CLINICA CHIMICA ACTA, 2025, 572
  • [30] Does NT-proBNP testing reduce costs and improve accuracy in the diagnosis of heart failure?
    A Mark Richards
    Nature Clinical Practice Cardiovascular Medicine, 2007, 4 : 652 - 653